<PubmedArticle><MedlineCitation Status="PubMed-not-MEDLINE" Owner="NLM"><PMID Version="1">38792840</PMID><DateRevised><Year>2024</Year><Month>05</Month><Day>27</Day></DateRevised><Article PubModel="Electronic"><Journal><ISSN IssnType="Print">2076-2607</ISSN><JournalIssue CitedMedium="Print"><Volume>12</Volume><Issue>5</Issue><PubDate><Year>2024</Year><Month>May</Month><Day>17</Day></PubDate></JournalIssue><Title>Microorganisms</Title><ISOAbbreviation>Microorganisms</ISOAbbreviation></Journal><ArticleTitle>In-Host Flat-like Quasispecies: Characterization Methods and Clinical Implications.</ArticleTitle><ELocationID EIdType="pii" ValidYN="Y">1011</ELocationID><ELocationID EIdType="doi" ValidYN="Y">10.3390/microorganisms12051011</ELocationID><Abstract><AbstractText>The repeated failure to treat patients chronically infected with hepatitis E (HEV) and C (HCV) viruses, despite the absence of resistance-associated substitutions (RAS), particularly in response to prolonged treatments with the mutagenic agents of HEV, suggests that quasispecies structure may play a crucial role beyond single point mutations. Quasispecies structured in a flat-like manner (referred to as flat-like) are considered to possess high average fitness, occupy a significant fraction of the functional genetic space of the virus, and exhibit a high capacity to evade specific or mutagenic treatments. In this paper, we studied HEV and HCV samples using high-depth next-generation sequencing (NGS), with indices scoring the different properties describing flat-like quasispecies. The significance of these indices was demonstrated by comparing the values obtained from these samples with those from acute infections caused by respiratory viruses (betacoronaviruses, enterovirus, respiratory syncytial viruses, and metapneumovirus). Our results revealed that flat-like quasispecies in HEV and HCV chronic infections without RAS are characterized by numerous low-frequency haplotypes with no dominant one. Surprisingly, these low-frequency haplotypes (at the nucleotide level) exhibited a high level of synonymity, resulting in much lower diversity at the phenotypic level. Currently, clinical approaches for managing flat-like quasispecies are lacking. Here, we propose methods to identifying flat-like quasispecies, which represents an essential initial step towards exploring alternative treatment protocols for viruses resistant to conventional therapies.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Gregori</LastName><ForeName>Josep</ForeName><Initials>J</Initials><Identifier Source="ORCID">0000-0002-4253-8015</Identifier><AffiliationInfo><Affiliation>Liver Diseases-Viral Hepatitis, Liver Unit, Vall d'Hebron Institut of Research (VHIR), Vall d'Hebron Barcelona Hospital Campus, Passeig Vall d'Hebron 119-129, 08035 Barcelona, Spain.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Colomer-Castell</LastName><ForeName>Sergi</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>Liver Diseases-Viral Hepatitis, Liver Unit, Vall d'Hebron Institut of Research (VHIR), Vall d'Hebron Barcelona Hospital Campus, Passeig Vall d'Hebron 119-129, 08035 Barcelona, Spain.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Centro de Investigación Biomédica en Red de Enfermedades Hepáticas y Digestivas (CIBEREHD), Instituto de Salud Carlos III, Av. Monforte de Lemos, 3-5, 28029 Madrid, Spain.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Biochemistry and Molecular Biology Department, Universitat Autònoma de Barcelona (UAB), Campus de la UAB, Plaça Cívica, 08193 Bellaterra, Spain.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Ibañez-Lligoña</LastName><ForeName>Marta</ForeName><Initials>M</Initials><Identifier Source="ORCID">0000-0003-3428-2168</Identifier><AffiliationInfo><Affiliation>Liver Diseases-Viral Hepatitis, Liver Unit, Vall d'Hebron Institut of Research (VHIR), Vall d'Hebron Barcelona Hospital Campus, Passeig Vall d'Hebron 119-129, 08035 Barcelona, Spain.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Centro de Investigación Biomédica en Red de Enfermedades Hepáticas y Digestivas (CIBEREHD), Instituto de Salud Carlos III, Av. Monforte de Lemos, 3-5, 28029 Madrid, Spain.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Medicine Department, Universitat Autònoma de Barcelona (UAB), Campus de la UAB, Plaça Cívica, 08193 Bellaterra, Spain.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Garcia-Cehic</LastName><ForeName>Damir</ForeName><Initials>D</Initials><Identifier Source="ORCID">0000-0002-0009-038X</Identifier><AffiliationInfo><Affiliation>Liver Diseases-Viral Hepatitis, Liver Unit, Vall d'Hebron Institut of Research (VHIR), Vall d'Hebron Barcelona Hospital Campus, Passeig Vall d'Hebron 119-129, 08035 Barcelona, Spain.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Centro de Investigación Biomédica en Red de Enfermedades Hepáticas y Digestivas (CIBEREHD), Instituto de Salud Carlos III, Av. Monforte de Lemos, 3-5, 28029 Madrid, Spain.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Campos</LastName><ForeName>Carolina</ForeName><Initials>C</Initials><Identifier Source="ORCID">0000-0002-0132-7027</Identifier><AffiliationInfo><Affiliation>Liver Diseases-Viral Hepatitis, Liver Unit, Vall d'Hebron Institut of Research (VHIR), Vall d'Hebron Barcelona Hospital Campus, Passeig Vall d'Hebron 119-129, 08035 Barcelona, Spain.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Centro de Investigación Biomédica en Red de Enfermedades Hepáticas y Digestivas (CIBEREHD), Instituto de Salud Carlos III, Av. Monforte de Lemos, 3-5, 28029 Madrid, Spain.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Biochemistry and Molecular Biology Department, Universitat Autònoma de Barcelona (UAB), Campus de la UAB, Plaça Cívica, 08193 Bellaterra, Spain.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Buti</LastName><ForeName>Maria</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Liver Diseases-Viral Hepatitis, Liver Unit, Vall d'Hebron Institut of Research (VHIR), Vall d'Hebron Barcelona Hospital Campus, Passeig Vall d'Hebron 119-129, 08035 Barcelona, Spain.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Centro de Investigación Biomédica en Red de Enfermedades Hepáticas y Digestivas (CIBEREHD), Instituto de Salud Carlos III, Av. Monforte de Lemos, 3-5, 28029 Madrid, Spain.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Medicine Department, Universitat Autònoma de Barcelona (UAB), Campus de la UAB, Plaça Cívica, 08193 Bellaterra, Spain.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Riveiro-Barciela</LastName><ForeName>Mar</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Liver Diseases-Viral Hepatitis, Liver Unit, Vall d'Hebron Institut of Research (VHIR), Vall d'Hebron Barcelona Hospital Campus, Passeig Vall d'Hebron 119-129, 08035 Barcelona, Spain.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Centro de Investigación Biomédica en Red de Enfermedades Hepáticas y Digestivas (CIBEREHD), Instituto de Salud Carlos III, Av. Monforte de Lemos, 3-5, 28029 Madrid, Spain.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Medicine Department, Universitat Autònoma de Barcelona (UAB), Campus de la UAB, Plaça Cívica, 08193 Bellaterra, Spain.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Andrés</LastName><ForeName>Cristina</ForeName><Initials>C</Initials><AffiliationInfo><Affiliation>Centro de Investigación Biomédica en Red de Enfermedades Infecciosas (CIBERINFEC), Instituto de Salud Carlos III, Av. Monforte de Lemos, 3-5, 28029 Madrid, Spain.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Microbiology Department, Vall d'Hebron Institut de Recerca (VHIR), Vall d'Hebron Barcelona Hospital Campus, Passeig Vall d'Hebron 119-129, 08035 Barcelona, Spain.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Piñana</LastName><ForeName>Maria</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Centro de Investigación Biomédica en Red de Enfermedades Infecciosas (CIBERINFEC), Instituto de Salud Carlos III, Av. Monforte de Lemos, 3-5, 28029 Madrid, Spain.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Microbiology Department, Vall d'Hebron Institut de Recerca (VHIR), Vall d'Hebron Barcelona Hospital Campus, Passeig Vall d'Hebron 119-129, 08035 Barcelona, Spain.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>González-Sánchez</LastName><ForeName>Alejandra</ForeName><Initials>A</Initials><Identifier Source="ORCID">0000-0002-1809-3415</Identifier><AffiliationInfo><Affiliation>Centro de Investigación Biomédica en Red de Enfermedades Infecciosas (CIBERINFEC), Instituto de Salud Carlos III, Av. Monforte de Lemos, 3-5, 28029 Madrid, Spain.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Microbiology Department, Vall d'Hebron Institut de Recerca (VHIR), Vall d'Hebron Barcelona Hospital Campus, Passeig Vall d'Hebron 119-129, 08035 Barcelona, Spain.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Rodriguez-Frias</LastName><ForeName>Francisco</ForeName><Initials>F</Initials><Identifier Source="ORCID">0000-0002-9128-7013</Identifier><AffiliationInfo><Affiliation>Centro de Investigación Biomédica en Red de Enfermedades Hepáticas y Digestivas (CIBEREHD), Instituto de Salud Carlos III, Av. Monforte de Lemos, 3-5, 28029 Madrid, Spain.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Biochemistry Department, Vall d'Hebron Institut de Recerca (VHIR), Vall d'Hebron Barcelona Hospital Campus, Passeig Vall d'Hebron 119-129, 08035 Barcelona, Spain.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Basic Science Department, International University of Catalonia, Sant Cugat del Vallès, 08195 Barcelona, Spain.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Cortese</LastName><ForeName>Maria Francesca</ForeName><Initials>MF</Initials><Identifier Source="ORCID">0000-0002-4318-532X</Identifier><AffiliationInfo><Affiliation>Centro de Investigación Biomédica en Red de Enfermedades Hepáticas y Digestivas (CIBEREHD), Instituto de Salud Carlos III, Av. Monforte de Lemos, 3-5, 28029 Madrid, Spain.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Microbiology Department, Vall d'Hebron Institut de Recerca (VHIR), Vall d'Hebron Barcelona Hospital Campus, Passeig Vall d'Hebron 119-129, 08035 Barcelona, Spain.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Tabernero</LastName><ForeName>David</ForeName><Initials>D</Initials><Identifier Source="ORCID">0000-0002-1146-4084</Identifier><AffiliationInfo><Affiliation>Liver Diseases-Viral Hepatitis, Liver Unit, Vall d'Hebron Institut of Research (VHIR), Vall d'Hebron Barcelona Hospital Campus, Passeig Vall d'Hebron 119-129, 08035 Barcelona, Spain.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Centro de Investigación Biomédica en Red de Enfermedades Hepáticas y Digestivas (CIBEREHD), Instituto de Salud Carlos III, Av. Monforte de Lemos, 3-5, 28029 Madrid, Spain.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Biochemistry Department, Vall d'Hebron Institut de Recerca (VHIR), Vall d'Hebron Barcelona Hospital Campus, Passeig Vall d'Hebron 119-129, 08035 Barcelona, Spain.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Rando-Segura</LastName><ForeName>Ariadna</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Centro de Investigación Biomédica en Red de Enfermedades Hepáticas y Digestivas (CIBEREHD), Instituto de Salud Carlos III, Av. Monforte de Lemos, 3-5, 28029 Madrid, Spain.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Microbiology Department, Vall d'Hebron Institut de Recerca (VHIR), Vall d'Hebron Barcelona Hospital Campus, Passeig Vall d'Hebron 119-129, 08035 Barcelona, Spain.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Pumarola</LastName><ForeName>Tomás</ForeName><Initials>T</Initials><AffiliationInfo><Affiliation>Biochemistry and Molecular Biology Department, Universitat Autònoma de Barcelona (UAB), Campus de la UAB, Plaça Cívica, 08193 Bellaterra, Spain.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Centro de Investigación Biomédica en Red de Enfermedades Infecciosas (CIBERINFEC), Instituto de Salud Carlos III, Av. Monforte de Lemos, 3-5, 28029 Madrid, Spain.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Microbiology Department, Vall d'Hebron Institut de Recerca (VHIR), Vall d'Hebron Barcelona Hospital Campus, Passeig Vall d'Hebron 119-129, 08035 Barcelona, Spain.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Biochemistry Department, Vall d'Hebron Institut de Recerca (VHIR), Vall d'Hebron Barcelona Hospital Campus, Passeig Vall d'Hebron 119-129, 08035 Barcelona, Spain.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Esteban</LastName><ForeName>Juan Ignacio</ForeName><Initials>JI</Initials><AffiliationInfo><Affiliation>Liver Diseases-Viral Hepatitis, Liver Unit, Vall d'Hebron Institut of Research (VHIR), Vall d'Hebron Barcelona Hospital Campus, Passeig Vall d'Hebron 119-129, 08035 Barcelona, Spain.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Centro de Investigación Biomédica en Red de Enfermedades Hepáticas y Digestivas (CIBEREHD), Instituto de Salud Carlos III, Av. Monforte de Lemos, 3-5, 28029 Madrid, Spain.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Medicine Department, Universitat Autònoma de Barcelona (UAB), Campus de la UAB, Plaça Cívica, 08193 Bellaterra, Spain.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Antón</LastName><ForeName>Andrés</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Centro de Investigación Biomédica en Red de Enfermedades Infecciosas (CIBERINFEC), Instituto de Salud Carlos III, Av. Monforte de Lemos, 3-5, 28029 Madrid, Spain.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Microbiology Department, Vall d'Hebron Institut de Recerca (VHIR), Vall d'Hebron Barcelona Hospital Campus, Passeig Vall d'Hebron 119-129, 08035 Barcelona, Spain.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Quer</LastName><ForeName>Josep</ForeName><Initials>J</Initials><Identifier Source="ORCID">0000-0003-0014-084X</Identifier><AffiliationInfo><Affiliation>Liver Diseases-Viral Hepatitis, Liver Unit, Vall d'Hebron Institut of Research (VHIR), Vall d'Hebron Barcelona Hospital Campus, Passeig Vall d'Hebron 119-129, 08035 Barcelona, Spain.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Centro de Investigación Biomédica en Red de Enfermedades Hepáticas y Digestivas (CIBEREHD), Instituto de Salud Carlos III, Av. Monforte de Lemos, 3-5, 28029 Madrid, Spain.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Biochemistry and Molecular Biology Department, Universitat Autònoma de Barcelona (UAB), Campus de la UAB, Plaça Cívica, 08193 Bellaterra, Spain.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Medicine Department, Universitat Autònoma de Barcelona (UAB), Campus de la UAB, Plaça Cívica, 08193 Bellaterra, Spain.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><GrantID>PI19/00301 &amp; PI22/00258</GrantID><Agency>Instituto de Salud Carlos III (ISCIII) and cofounded by the European Union</Agency><Country /></Grant><Grant><GrantID>IDI-20200297</GrantID><Agency>Centro para el Desarrollo Tecnológico Industrial (CDTI) from the Spanish Ministry of Economy and Business</Agency><Country /></Grant><Grant><GrantID>PID2021-126447OB-I00</GrantID><Agency>MCIN/AEI/10.13039/501100011033 and by ERDF A way of making Europe</Agency><Country /></Grant><Grant><GrantID>FPU21/04150</GrantID><Agency>S.C.-C has received support from Spanish Ministry of Education</Agency><Country /></Grant><Grant><GrantID>LCF/BQ/DR23/12000020</GrantID><Agency>M.I.-L. received the support of a fellowship from "La Caixa" Foundation (ID 100010434)</Agency><Country /></Grant></GrantList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2024</Year><Month>05</Month><Day>17</Day></ArticleDate></Article><MedlineJournalInfo><Country>Switzerland</Country><MedlineTA>Microorganisms</MedlineTA><NlmUniqueID>101625893</NlmUniqueID><ISSNLinking>2076-2607</ISSNLinking></MedlineJournalInfo><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">enhanced fitness</Keyword><Keyword MajorTopicYN="N">flat-like quasispecies</Keyword><Keyword MajorTopicYN="N">mutagens</Keyword><Keyword MajorTopicYN="N">near-flat</Keyword><Keyword MajorTopicYN="N">regular quasispecies</Keyword><Keyword MajorTopicYN="N">resistance-associated mutations (RAS)</Keyword><Keyword MajorTopicYN="N">viral treatment failures</Keyword></KeywordList><CoiStatement>The authors declare no conflicts of interest.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2024</Year><Month>3</Month><Day>20</Day></PubMedPubDate><PubMedPubDate PubStatus="revised"><Year>2024</Year><Month>5</Month><Day>8</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2024</Year><Month>5</Month><Day>14</Day></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2024</Year><Month>5</Month><Day>25</Day><Hour>10</Hour><Minute>49</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2024</Year><Month>5</Month><Day>25</Day><Hour>10</Hour><Minute>48</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2024</Year><Month>5</Month><Day>25</Day><Hour>1</Hour><Minute>18</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2024</Year><Month>5</Month><Day>17</Day></PubMedPubDate></History><PublicationStatus>epublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">38792840</ArticleId><ArticleId IdType="pmc">PMC11124460</ArticleId><ArticleId IdType="doi">10.3390/microorganisms12051011</ArticleId><ArticleId IdType="pii">microorganisms12051011</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Chen Q., Perales C., Soria M.E., García-Cehic D., Gregori J., Rodríguez-Frías F., Buti M., Crespo J., Calleja J.L., Tabernero D., et al. Deep-Sequencing Reveals Broad Subtype-Specific HCV Resistance Mutations Associated with Treatment Failure. Antivir. Res. 2020;174:104694. doi: 10.1016/j.antiviral.2019.104694.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.antiviral.2019.104694</ArticleId><ArticleId IdType="pubmed">31857134</ArticleId></ArticleIdList></Reference><Reference><Citation>Stuart J.D., Salinas E., Grakoui A. Immune System Control of Hepatitis C Virus Infection. Curr. Opin. Virol. 2021;46:36–44. doi: 10.1016/j.coviro.2020.10.002.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.coviro.2020.10.002</ArticleId><ArticleId IdType="pmc">PMC7979439</ArticleId><ArticleId IdType="pubmed">33137689</ArticleId></ArticleIdList></Reference><Reference><Citation>Chigbu D.I., Loonawat R., Sehgal M., Patel D., Jain P. Hepatitis C Virus Infection: Host–Virus Interaction and Mechanisms of Viral Persistence. Cells. 2019;8:376. doi: 10.3390/cells8040376.</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/cells8040376</ArticleId><ArticleId IdType="pmc">PMC6523734</ArticleId><ArticleId IdType="pubmed">31027278</ArticleId></ArticleIdList></Reference><Reference><Citation>Sorbo M.C., Cento V., Di Maio V.C., Howe A.Y.M., Garcia F., Perno C.F., Ceccherini-Silberstein F. Hepatitis C Virus Drug Resistance Associated Substitutions and Their Clinical Relevance: Update 2018. Drug Resist. 2018;37:17–39.</Citation><ArticleIdList><ArticleId IdType="pubmed">29525636</ArticleId></ArticleIdList></Reference><Reference><Citation>Vignuzzi M., Stone J.K., Arnold J.J., Cameron C.E., Andino R. Quasispecies Diversity Determines Pathogenesis through Cooperative Interactions in a Viral Population. Nature. 2006;439:344–348. doi: 10.1038/nature04388.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/nature04388</ArticleId><ArticleId IdType="pmc">PMC1569948</ArticleId><ArticleId IdType="pubmed">16327776</ArticleId></ArticleIdList></Reference><Reference><Citation>Domingo E., Menéndez-Arias L., Holland J.J. RNA Virus Fitness. Rev. Med. Virol. 1997;7:87–96. doi: 10.1002/(sici)1099-1654(199707)7:2&lt;87::aid-rmv188&gt;3.0.co;2-0.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/(sici)1099-1654(199707)7:2&lt;87::aid-rmv188&gt;3.0.co;2-0</ArticleId><ArticleId IdType="pubmed">10398474</ArticleId></ArticleIdList></Reference><Reference><Citation>Andino R., Domingo E. Viral Quasispecies. Virology. 2015;479–480:46–51. doi: 10.1016/j.virol.2015.03.022.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.virol.2015.03.022</ArticleId><ArticleId IdType="pmc">PMC4826558</ArticleId><ArticleId IdType="pubmed">25824477</ArticleId></ArticleIdList></Reference><Reference><Citation>Volz E., Mishra S., Chand M., Barrett J.C., Johnson R., Geidelberg L., Hinsley W.R., Laydon D.J., Dabrera G., O’Toole Á., et al. Assessing Transmissibility of SARS-CoV-2 Lineage B.1.1.7 in England. Nature. 2021;593:266–269. doi: 10.1038/s41586-021-03470-x.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41586-021-03470-x</ArticleId><ArticleId IdType="pubmed">33767447</ArticleId></ArticleIdList></Reference><Reference><Citation>Wilke C.O., Wang J.L., Ofria C., Lenski R.E., Adami C. Evolution of Digital Organisms at High Mutation Rates Leads to Survival of the Flattest. Nature. 2001;412:331–333. doi: 10.1038/35085569.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/35085569</ArticleId><ArticleId IdType="pubmed">11460163</ArticleId></ArticleIdList></Reference><Reference><Citation>Wilke C.O. Quasispecies Theory in the Context of Population Genetics. BMC Evol. Biol. 2005;5:44. doi: 10.1186/1471-2148-5-44.</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/1471-2148-5-44</ArticleId><ArticleId IdType="pmc">PMC1208876</ArticleId><ArticleId IdType="pubmed">16107214</ArticleId></ArticleIdList></Reference><Reference><Citation>Lauring A.S., Andino R. Quasispecies Theory and the Behavior of RNA Viruses. PLoS Pathog. 2010;6:e1001005. doi: 10.1371/journal.ppat.1001005.</Citation><ArticleIdList><ArticleId IdType="doi">10.1371/journal.ppat.1001005</ArticleId><ArticleId IdType="pmc">PMC2908548</ArticleId><ArticleId IdType="pubmed">20661479</ArticleId></ArticleIdList></Reference><Reference><Citation>Clark P.J., Valery P.C., Strasser S.I., Weltman M., Thompson A.J., Levy M., Leggett B., Zekry A., Rong J., Angus P., et al. Liver Disease and Poor Adherence Limit Hepatitis C Cure: A Real-World Australian Treatment Cohort. Dig. Dis. Sci. 2023;68:291–303. doi: 10.1007/s10620-022-07483-y.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s10620-022-07483-y</ArticleId><ArticleId IdType="pmc">PMC9883319</ArticleId><ArticleId IdType="pubmed">35552941</ArticleId></ArticleIdList></Reference><Reference><Citation>European Association for the Study of the Liver EASL 2017 Clinical Practice Guidelines on the Management of Hepatitis B Virus Infection. J. Hepatol. 2017;67:370–398. doi: 10.1016/j.jhep.2017.03.021.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jhep.2017.03.021</ArticleId><ArticleId IdType="pubmed">28427875</ArticleId></ArticleIdList></Reference><Reference><Citation>Colomer-Castell S., Gregori J., Garcia-Cehic D., Riveiro-Barciela M., Buti M., Rando-Segura A., Vico-Romero J., Campos C., Ibañez-Lligoña M., Adombie C.M., et al. In-Host HEV Quasispecies Evolution Show the Limits of Mutagenic Antiviral Treatments. Int. J. Mol. Sci. 2023;24:17185. doi: 10.3390/ijms242417185.</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/ijms242417185</ArticleId><ArticleId IdType="pmc">PMC10743355</ArticleId><ArticleId IdType="pubmed">38139013</ArticleId></ArticleIdList></Reference><Reference><Citation>Gregori J., Colomer-Castell S., Campos C., Ibañez-Lligoña M., Garcia-Cehic D., Rando-Segura A., Adombie C.M., Pintó R., Guix S., Bosch A., et al. Quasispecies Fitness Partition to Characterize the Molecular Status of a Viral Population. Negative Effect of Early Ribavirin Discontinuation in a Chronically Infected HEV Patient. Int. J. Mol. Sci. 2022;23:14654. doi: 10.3390/ijms232314654.</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/ijms232314654</ArticleId><ArticleId IdType="pmc">PMC9739305</ArticleId><ArticleId IdType="pubmed">36498981</ArticleId></ArticleIdList></Reference><Reference><Citation>Campos C., Colomer-Castell S., Garcia-Cehic D., Gregori J., Andrés C., Piñana M., González-Sánchez A., Borràs B., Parés-Badell O., Adombi C.M., et al. The Frequency of Defective Genomes in Omicron Differs from That of the Alpha, Beta and Delta Variants. Sci. Rep. 2022;12:22571. doi: 10.1038/s41598-022-24918-8.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41598-022-24918-8</ArticleId><ArticleId IdType="pmc">PMC9799681</ArticleId><ArticleId IdType="pubmed">36581627</ArticleId></ArticleIdList></Reference><Reference><Citation>Adombie C.M., Bosch A., Buti M., Campos C., Colomer-Castell S., Cortese M.F., Domingo E., Esteban J.I., Gallego I., Garcia-Cehic D., et al. In: Viral Quasispecies Diversity and Evolution. A Bioinformatics Molecular Approach. 1st ed. Gregori J., Rodríguez-Frías F., Quer J., editors. II Pensiero Scientific Editore; Rome, Italy: 2023.</Citation></Reference><Reference><Citation>Magoc T., Salzberg S.L. FLASH: Fast Length Adjustment of Short Reads to Improve Genome Assemblies. Bioinformatics. 2011;27:2957–2963. doi: 10.1093/bioinformatics/btr507.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/bioinformatics/btr507</ArticleId><ArticleId IdType="pmc">PMC3198573</ArticleId><ArticleId IdType="pubmed">21903629</ArticleId></ArticleIdList></Reference><Reference><Citation>Hill M.O. Diversity and Evenness: A Unifying Notation and Its Consequences. Ecology. 1973;54:427–432. doi: 10.2307/1934352.</Citation><ArticleIdList><ArticleId IdType="doi">10.2307/1934352</ArticleId></ArticleIdList></Reference><Reference><Citation>Jost L. The Relation between Evenness and Diversity. Diversity. 2010;2:207–232. doi: 10.3390/d2020207.</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/d2020207</ArticleId></ArticleIdList></Reference><Reference><Citation>Studeny A., Buckland S., Illian J., Johnson A., Magurran A. Goodness-of-Fit Measures of Evenness: A New Tool for Exploring Changes in Community Structure. Ecosphere. 2011;2:1–19. doi: 10.1890/ES10-00074.1.</Citation><ArticleIdList><ArticleId IdType="doi">10.1890/ES10-00074.1</ArticleId></ArticleIdList></Reference><Reference><Citation>Kvålseth T.O. Evenness Indices Once Again: Critical Analysis of Properties. Springerplus. 2015;4:232. doi: 10.1186/s40064-015-0944-4.</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/s40064-015-0944-4</ArticleId><ArticleId IdType="pmc">PMC4439415</ArticleId><ArticleId IdType="pubmed">26020023</ArticleId></ArticleIdList></Reference><Reference><Citation>Chávez E., Navarro G., Baeza-Yates R., Marroquíin J.L. Searching in Metric Spaces. ACM Comput. Surv. 2001;33:273–321. doi: 10.1145/502807.502808.</Citation><ArticleIdList><ArticleId IdType="doi">10.1145/502807.502808</ArticleId></ArticleIdList></Reference><Reference><Citation>Howe A.Y.M., Rodrigo C., Cunningham E.B., Douglas M.W., Dietz J., Grebely J., Popping S., Sfalcin J.A., Parczewski M., Sarrazin C., et al. Characteristics of Hepatitis C Virus Resistance in an International Cohort after a Decade of Direct-Acting Antivirals. JHEP Rep. 2022;4:100462. doi: 10.1016/j.jhepr.2022.100462.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jhepr.2022.100462</ArticleId><ArticleId IdType="pmc">PMC9010635</ArticleId><ArticleId IdType="pubmed">35434589</ArticleId></ArticleIdList></Reference><Reference><Citation>Perales C., Chen Q., Soria M.E., Gregori J., Garcia-Cehic D., Nieto-Aponte L., Castells L., Imaz A., Llorens-Revull M., Domingo E., et al. Baseline Hepatitis C Virus Resistance-Associated Substitutions Present at Frequencies Lower than 15% May Be Clinically Significant. Infect. Drug Resist. 2018;11:2207–2210. doi: 10.2147/IDR.S172226.</Citation><ArticleIdList><ArticleId IdType="doi">10.2147/IDR.S172226</ArticleId><ArticleId IdType="pmc">PMC6233951</ArticleId><ArticleId IdType="pubmed">30519058</ArticleId></ArticleIdList></Reference><Reference><Citation>Martinez M.A., Franco S. Therapy Implications of Hepatitis C Virus Genetic Diversity. Viruses. 2020;13:41. doi: 10.3390/v13010041.</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/v13010041</ArticleId><ArticleId IdType="pmc">PMC7824680</ArticleId><ArticleId IdType="pubmed">33383891</ArticleId></ArticleIdList></Reference><Reference><Citation>Sarrazin C. The Importance of Resistance to Direct Antiviral Drugs in HCV Infection in Clinical Practice. J. Hepatol. 2016;64:486–504. doi: 10.1016/j.jhep.2015.09.011.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jhep.2015.09.011</ArticleId><ArticleId IdType="pubmed">26409317</ArticleId></ArticleIdList></Reference><Reference><Citation>Domingo E., de Ávila A.I., Gallego I., Sheldon J., Perales C. Viral Fitness: History and Relevance for Viral Pathogenesis and Antiviral Interventions. Pathog. Dis. 2019;77:ftz021. doi: 10.1093/femspd/ftz021.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/femspd/ftz021</ArticleId><ArticleId IdType="pubmed">30980658</ArticleId></ArticleIdList></Reference><Reference><Citation>Soni S., Singh D., Aggarwal R., Veerapu N.S. Enhanced Fitness of Hepatitis C Virus Increases Resistance to Direct-Acting Antivirals. J. Gen. Virol. 2022;103:001699. doi: 10.1099/jgv.0.001699.</Citation><ArticleIdList><ArticleId IdType="doi">10.1099/jgv.0.001699</ArticleId><ArticleId IdType="pubmed">35133954</ArticleId></ArticleIdList></Reference><Reference><Citation>Donaldson E.F., Harrington P.R., O’Rear J.J., Naeger L.K. Clinical Evidence and Bioinformatics Characterization of Potential Hepatitis C Virus Resistance Pathways for Sofosbuvir. Hepatology. 2015;61:56–65. doi: 10.1002/hep.27375.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/hep.27375</ArticleId><ArticleId IdType="pubmed">25123381</ArticleId></ArticleIdList></Reference><Reference><Citation>Dietz J., Müllhaupt B., Buggisch P., Graf C., Peiffer K.-H., Matschenz K., Schattenberg J.M., Antoni C., Mauss S., Niederau C., et al. Long-Term Persistence of HCV Resistance-Associated Substitutions after DAA Treatment Failure. J. Hepatol. 2023;78:57–66. doi: 10.1016/j.jhep.2022.08.016.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jhep.2022.08.016</ArticleId><ArticleId IdType="pubmed">36031158</ArticleId></ArticleIdList></Reference><Reference><Citation>Walker A., Filke S., Lubke N., Obermeier M., Kaiser R., Haussinger D., Timm J., Bock H.H. Detection of a Genetic Footprint of the Sofosbuvir Resistance-Associated Substitution S282T after HCV Treatment Failure. Virol. J. 2017;14:106. doi: 10.1186/s12985-017-0779-4.</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/s12985-017-0779-4</ArticleId><ArticleId IdType="pmc">PMC5465446</ArticleId><ArticleId IdType="pubmed">28595606</ArticleId></ArticleIdList></Reference><Reference><Citation>Sarrazin C., Dvory-Sobol H., Svarovskaia E.S., Doehle B.P., Pang P.S., Chuang S.M., Ma J., Ding X., Afdhal N.H., Kowdley K.V., et al. Prevalence of Resistance-Associated Substitutions in HCV NS5A, NS5B, or NS3 and Outcomes of Treatment with Ledipasvir and Sofosbuvir. Gastroenterology. 2016;151:501–512. doi: 10.1053/j.gastro.2016.06.002.</Citation><ArticleIdList><ArticleId IdType="doi">10.1053/j.gastro.2016.06.002</ArticleId><ArticleId IdType="pubmed">27296509</ArticleId></ArticleIdList></Reference><Reference><Citation>Domingo E., Holland J.J. Mutation Rates and Rapid Evolution of RNA Viruses. In: Morse S.S., editor. Evolutionary Biology of Viruses. Raven Press; New York, NY, USA: 1994. pp. 161–184.</Citation></Reference><Reference><Citation>Domingo E. Viruses at the Edge of Adaptation. Virology. 2000;270:251–253. doi: 10.1006/viro.2000.0320.</Citation><ArticleIdList><ArticleId IdType="doi">10.1006/viro.2000.0320</ArticleId><ArticleId IdType="pubmed">10792982</ArticleId></ArticleIdList></Reference><Reference><Citation>Domingo E., Escarmis C., Lazaro E., Manrubia S.C. Quasispecies Dynamics and RNA Virus Extinction. Virus Res. 2005;107:129–139. doi: 10.1016/j.virusres.2004.11.003.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.virusres.2004.11.003</ArticleId><ArticleId IdType="pubmed">15649559</ArticleId></ArticleIdList></Reference><Reference><Citation>Domingo E., Perales C. Viral Quasispecies. PLoS Genet. 2019;15:e1008271. doi: 10.1371/journal.pgen.1008271.</Citation><ArticleIdList><ArticleId IdType="doi">10.1371/journal.pgen.1008271</ArticleId><ArticleId IdType="pmc">PMC6797082</ArticleId><ArticleId IdType="pubmed">31622336</ArticleId></ArticleIdList></Reference><Reference><Citation>Novella I.S. Contributions of Vesicular Stomatitis Virus to the Understanding of RNA Virus Evolution. Curr.Opin. Microbiol. 2003;6:399–405. doi: 10.1016/S1369-5274(03)00084-5.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S1369-5274(03)00084-5</ArticleId><ArticleId IdType="pubmed">12941412</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle>